Compare Levi Strauss & Co. (LEVI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Twist Bioscience Corp — how do they compare? Levi Strauss & Co. trades at $18.7 (market cap $7.31B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Levi Strauss & Co. pays a 3.36% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Twist Bioscience Corp for 27 Days on average.
| LEVI | TWST | |
|---|---|---|
Market Cap | $7.31B | $10.08B |
Volume | 13,683,095 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $205.00 |
52-Week Low | $17.92 | $25.45 |
Typical Hold Time | 70 Days | 27 Days |
Enterprise Value | $8.86B | $10.01B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss & Co. (LEVI) trades at $19.05, down 2.36% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for four consecutive quarters, including Q3 2026 EPS of $0.48 versus $0.36 expected. Financial health is robust with a net income margin of 8.83% and ROE of 25.76%. Recent news highlights a new CFO appointment and positive analyst expectations for Q3 results driven by denim demand trends.
The investment outlook is positive based on fundamentals and analyst sentiment, with a consensus price target of $29.00 implying significant upside. Risks include competitive pressures, recent cybersecurity incidents, and macroeconomic sensitivity. Wall Street maintains a strong buy consensus, supporting a favorable risk-reward profile for long-term investors.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
